Restricted treatments, inducements, and research participation.
In this paper, I support the claim that placing certain restrictions on public access to possible new treatments is morally problematic under some exceptional circumstances. Very ill patients may find that all available standard treatments are unacceptable, either because they are ineffective or have serious adverse effects, and these patients may understandably be desperate to try something new even if this means stepping into the unknown. Faced with certain death, it is rational to want to try something new and to chance a dire outcome. Restricting possible new treatments to research trials may put these treatments scientifically, geographically or economically out of reach of these patients. For those who can get access, research restrictions could weaken, though not necessarily eliminate, the value of consent participants of such trials are able to give. Some participants may therefore be exploited for scientific purposes in the name of public interest. There are nonetheless compelling reasons for keeping some restrictive regulation in this area.
Edwards
Sarah J L
SJ
Centre for Bioethics and Philosophy of Medicine UCL, Research & Development Directorate, University College London Hospitals NHS Trust, London W1P 9LL, UK. sarah.edwards1@uclh.org
D002986:Clinical Trials as Topic / Q000941:ethics*; D003068:Coercion; D034723:Double Effect Principle; D017277:Drug Approval; D004345:Drug Industry; D015507:Drugs, Investigational / Q000191:economics / Q000600:supply & distribution*; D026689:Ethical Analysis; D005610:Freedom; D033161:Government Regulation; D006297:Health Services Accessibility / Q000191:economics / Q000941:ethics; D006805:Human Experimentation / Q000941:ethics; D006801:Humans; D007258:Informed Consent; D019458:Insurance Coverage; D038622:Internationality; D009042:Motivation; D026706:Paternalism / Q000941:ethics*; D010361:Patients; D010684:Philosophy; D035842:Research Subjects; D018570:Risk Assessment; D012935:Social Justice; D035862:Vulnerable Populations
D015507:Drugs, Investigational